JP2009507801A5

JP2009507801A5 -

Download PDF

Info

Publication number: JP2009507801A5
Authority: JP; Japan
Prior art keywords: mmol; added; solution; compound; stirred
Prior art date: 2006-09-07
Legal status : Granted

Application number

JP2008529564A

Other languages

English (en)

Japanese (ja)

Other versions

JP2009507801A (ja

JP5121716B2 (ja

Filing date

2006-09-07

Publication date

2012-10-25

2005-09-09 Priority claimed from GB0518472A external-priority patent/GB0518472D0/en

2006-06-06 Priority claimed from GB0611153A external-priority patent/GB0611153D0/en

2006-09-07 Application filed filed Critical

2006-09-07 Priority claimed from PCT/EP2006/008845 external-priority patent/WO2007028654A1/en

2009-02-26 Publication of JP2009507801A publication Critical patent/JP2009507801A/ja

2012-10-25 Publication of JP2009507801A5 publication Critical patent/JP2009507801A5/ja

2013-01-16 Application granted granted Critical

2013-01-16 Publication of JP5121716B2 publication Critical patent/JP5121716B2/ja

Status Active legal-status Critical Current

2026-09-07 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims description 321
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 163
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 156
-1 4- fluoro-2-methylphenyl Chemical group 0.000 claims description 85
150000003839 salts Chemical class 0.000 claims description 55
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
208000035475 disorder Diseases 0.000 claims description 45
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 32
208000020016 psychiatric disease Diseases 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 12
201000000980 schizophrenia Diseases 0.000 claims description 11
208000007848 Alcoholism Diseases 0.000 claims description 8
208000028505 alcohol-related disease Diseases 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
208000020925 Bipolar disease Diseases 0.000 claims description 6
201000007930 alcohol dependence Diseases 0.000 claims description 6
208000020401 Depressive disease Diseases 0.000 claims description 5
208000028017 Psychotic disease Diseases 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 3
229940125782 compound 2 Drugs 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 508
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 458
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 353
239000000243 solution Substances 0.000 description 265
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 164
235000019439 ethyl acetate Nutrition 0.000 description 144
238000001819 mass spectrum Methods 0.000 description 139
239000002904 solvent Substances 0.000 description 138
238000006243 chemical reaction Methods 0.000 description 132
239000011541 reaction mixture Substances 0.000 description 115
239000000203 mixture Substances 0.000 description 109
125000000217 alkyl group Chemical group 0.000 description 103
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 98
239000000047 product Substances 0.000 description 89
229910052757 nitrogen Inorganic materials 0.000 description 88
238000005160 1H NMR spectroscopy Methods 0.000 description 87
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 87
239000007787 solid Substances 0.000 description 86
239000000377 silicon dioxide Substances 0.000 description 79
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 72
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 71
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 70
239000012043 crude product Substances 0.000 description 67
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 66
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 65
238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 65
238000005481 NMR spectroscopy Methods 0.000 description 62
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 59
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 54
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 52
229920006395 saturated elastomer Polymers 0.000 description 51
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
239000000460 chlorine Substances 0.000 description 50
230000002829 reductive effect Effects 0.000 description 50
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 47
125000004433 nitrogen atom Chemical group N* 0.000 description 47
238000000746 purification Methods 0.000 description 47
239000011734 sodium Substances 0.000 description 47
239000003153 chemical reaction reagent Substances 0.000 description 43
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 41
229910000041 hydrogen chloride Inorganic materials 0.000 description 41
238000003818 flash chromatography Methods 0.000 description 39
BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 37
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
229910000027 potassium carbonate Inorganic materials 0.000 description 36
239000000725 suspension Substances 0.000 description 36
239000008346 aqueous phase Substances 0.000 description 35
239000002585 base Substances 0.000 description 34
239000003921 oil Substances 0.000 description 33
235000019198 oils Nutrition 0.000 description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
238000004587 chromatography analysis Methods 0.000 description 32
238000010511 deprotection reaction Methods 0.000 description 32
125000003545 alkoxy group Chemical group 0.000 description 31
238000000034 method Methods 0.000 description 30
125000002887 hydroxy group Chemical group [H]O* 0.000 description 28
229910052736 halogen Inorganic materials 0.000 description 27
150000002367 halogens Chemical class 0.000 description 27
239000007864 aqueous solution Substances 0.000 description 26
239000008186 active pharmaceutical agent Substances 0.000 description 25
239000012071 phase Substances 0.000 description 24
239000012267 brine Substances 0.000 description 23
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
238000004458 analytical method Methods 0.000 description 22
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 22
229910052763 palladium Inorganic materials 0.000 description 22
229910052739 hydrogen Inorganic materials 0.000 description 21
239000013058 crude material Substances 0.000 description 20
239000001257 hydrogen Substances 0.000 description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
239000012074 organic phase Substances 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
239000000284 extract Substances 0.000 description 19
125000006239 protecting group Chemical group 0.000 description 19
238000003756 stirring Methods 0.000 description 19
239000002249 anxiolytic agent Substances 0.000 description 18
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
208000019901 Anxiety disease Diseases 0.000 description 17
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
239000002253 acid Substances 0.000 description 17
208000019116 sleep disease Diseases 0.000 description 17
BWHDROKFUHTORW-UHFFFAOYSA-N tri-tert-butylphosphine Substances CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 17
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
230000000949 anxiolytic effect Effects 0.000 description 16
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 16
238000010992 reflux Methods 0.000 description 16
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 16
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 15
125000002091 cationic group Chemical group 0.000 description 15
238000004128 high performance liquid chromatography Methods 0.000 description 15
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 15
239000007858 starting material Substances 0.000 description 15
TYRNNGZQKUKQJV-UHFFFAOYSA-N 1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]thiazine 2,2-dioxide Chemical compound C1CNCC2CS(=O)(=O)CCN21 TYRNNGZQKUKQJV-UHFFFAOYSA-N 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
239000012321 sodium triacetoxyborohydride Substances 0.000 description 14
239000000126 substance Substances 0.000 description 14
208000019022 Mood disease Diseases 0.000 description 13
IRLPJUXYSAAKGO-STQMWFEESA-N [(7s,9as)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1COC[C@@H]2CN[C@H](CO[Si](C)(C)C(C)(C)C)CN21 IRLPJUXYSAAKGO-STQMWFEESA-N 0.000 description 13
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 13
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 13
239000002244 precipitate Substances 0.000 description 13
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
206010012218 Delirium Diseases 0.000 description 12
125000002619 bicyclic group Chemical group 0.000 description 12
239000000706 filtrate Substances 0.000 description 12
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
239000000523 sample Substances 0.000 description 12
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 11
239000000935 antidepressant agent Substances 0.000 description 11
229940005513 antidepressants Drugs 0.000 description 11
229910052799 carbon Inorganic materials 0.000 description 11
239000003054 catalyst Substances 0.000 description 11
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 11
238000001914 filtration Methods 0.000 description 11
239000012299 nitrogen atmosphere Substances 0.000 description 11
125000004430 oxygen atom Chemical group O* 0.000 description 11
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 10
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 10
239000012317 TBTU Substances 0.000 description 10
150000002431 hydrogen Chemical class 0.000 description 10
230000014759 maintenance of location Effects 0.000 description 10
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 10
229910052760 oxygen Inorganic materials 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 10
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
208000022821 personality disease Diseases 0.000 description 9
239000012047 saturated solution Substances 0.000 description 9
ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 9
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
OPEBSOKNWMAPLB-YUMQZZPRSA-N [(7s,9as)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methanol Chemical compound C1COC[C@@H]2CN[C@H](CO)CN21 OPEBSOKNWMAPLB-YUMQZZPRSA-N 0.000 description 8
229940025084 amphetamine Drugs 0.000 description 8
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 8
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
229910000024 caesium carbonate Inorganic materials 0.000 description 8
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
239000000932 sedative agent Substances 0.000 description 8
230000001568 sexual effect Effects 0.000 description 8
229910000029 sodium carbonate Inorganic materials 0.000 description 8
YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 7
208000028810 Shared psychotic disease Diseases 0.000 description 7
239000000164 antipsychotic agent Substances 0.000 description 7
229940005529 antipsychotics Drugs 0.000 description 7
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 7
239000006260 foam Substances 0.000 description 7
238000010438 heat treatment Methods 0.000 description 7
229910052717 sulfur Chemical group 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
PJJLVZOKOWVMLN-LWOQYNTDSA-N (3r)-3-methyl-3,6,7,8,9,9a-hexahydro-2h-pyrazino[1,2-a]pyrazine-1,4-dione Chemical compound C1NCCN2C(=O)[C@@H](C)NC(=O)C21 PJJLVZOKOWVMLN-LWOQYNTDSA-N 0.000 description 6
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 6
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 6
208000022497 Cocaine-Related disease Diseases 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
208000026251 Opioid-Related disease Diseases 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
239000003638 chemical reducing agent Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
229910052731 fluorine Inorganic materials 0.000 description 6
239000011737 fluorine Substances 0.000 description 6
QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 6
235000019253 formic acid Nutrition 0.000 description 6
239000000380 hallucinogen Substances 0.000 description 6
229960002715 nicotine Drugs 0.000 description 6
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 6
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
230000001624 sedative effect Effects 0.000 description 6
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
208000011117 substance-related disease Diseases 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
238000004704 ultra performance liquid chromatography Methods 0.000 description 6
ZEKMVSOHQJAAHS-PHDIDXHHSA-N (7r,9as)-7-(hydroxymethyl)-2,2-dioxo-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]thiazine-6,9-dione Chemical compound C1S(=O)(=O)CCN2C(=O)[C@@H](CO)NC(=O)[C@H]21 ZEKMVSOHQJAAHS-PHDIDXHHSA-N 0.000 description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
XAUDKMAEBCEBDJ-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-n-[6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]cyclopropane-1-carboxamide Chemical compound CC1=CC(F)=CC=C1C1=CC(Cl)=NC=C1NC(=O)C1(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 XAUDKMAEBCEBDJ-UHFFFAOYSA-N 0.000 description 5
ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
208000029197 Amphetamine-Related disease Diseases 0.000 description 5
206010012289 Dementia Diseases 0.000 description 5
206010013654 Drug abuse Diseases 0.000 description 5
208000030814 Eating disease Diseases 0.000 description 5
208000019454 Feeding and Eating disease Diseases 0.000 description 5
206010026749 Mania Diseases 0.000 description 5
IRLPJUXYSAAKGO-QWHCGFSZSA-N [(7s,9ar)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1COC[C@H]2CN[C@H](CO[Si](C)(C)C(C)(C)C)CN21 IRLPJUXYSAAKGO-QWHCGFSZSA-N 0.000 description 5
JGLFLUHGPYMKTQ-GJZGRUSLSA-N [(7s,9as)-8-benzyl-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-7-yl]methanol Chemical compound C([C@H]1COCCN1C[C@H]1CO)N1CC1=CC=CC=C1 JGLFLUHGPYMKTQ-GJZGRUSLSA-N 0.000 description 5
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
239000012346 acetyl chloride Substances 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
229940005530 anxiolytics Drugs 0.000 description 5
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
229960003920 cocaine Drugs 0.000 description 5
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 5
235000014632 disordered eating Nutrition 0.000 description 5
206010013663 drug dependence Diseases 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
150000003840 hydrochlorides Chemical class 0.000 description 5
239000000463 material Substances 0.000 description 5
NDBQJIBNNUJNHA-AENDTGMFSA-N methyl (2r)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CO NDBQJIBNNUJNHA-AENDTGMFSA-N 0.000 description 5
125000002950 monocyclic group Chemical group 0.000 description 5
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 5
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 5
229950010883 phencyclidine Drugs 0.000 description 5
238000007363 ring formation reaction Methods 0.000 description 5
208000020685 sleep-wake disease Diseases 0.000 description 5
239000012279 sodium borohydride Substances 0.000 description 5
229910000033 sodium borohydride Inorganic materials 0.000 description 5
239000012453 solvate Substances 0.000 description 5
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
239000003643 water by type Substances 0.000 description 5
MGGVQZFQTOIVOD-RITPCOANSA-N (3r,9as)-3-(hydroxymethyl)-3,6,7,8,9,9a-hexahydro-2h-pyrazino[1,2-a]pyrazine-1,4-dione Chemical compound C1NCCN2C(=O)[C@@H](CO)NC(=O)[C@@H]21 MGGVQZFQTOIVOD-RITPCOANSA-N 0.000 description 4
ASXFMIDIRZPCGK-UHFFFAOYSA-N (4-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=NC=C1B(O)O ASXFMIDIRZPCGK-UHFFFAOYSA-N 0.000 description 4
BHFXPKPIPBNKFI-LURJTMIESA-N (8as)-2,3,4,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-6-one Chemical compound C1NCCN2C(=O)CC[C@H]21 BHFXPKPIPBNKFI-LURJTMIESA-N 0.000 description 4
BSBHJJOSYCWCIO-GJZGRUSLSA-N 1-[(7s,9as)-7-[[tert-butyl(dimethyl)silyl]oxymethyl]-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]ethanone Chemical compound C1[C@@H](CO[Si](C)(C)C(C)(C)C)NC[C@H]2CN(C(=O)C)CCN21 BSBHJJOSYCWCIO-GJZGRUSLSA-N 0.000 description 4
JWKUISVJTGPVGT-UHFFFAOYSA-N 2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazine Chemical compound C1CNCC2CNCCN21 JWKUISVJTGPVGT-UHFFFAOYSA-N 0.000 description 4
241000218236 Cannabis Species 0.000 description 4
206010012335 Dependence Diseases 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
208000003863 Marijuana Abuse Diseases 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
235000019502 Orange oil Nutrition 0.000 description 4
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
208000005374 Poisoning Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
SPZKTRAGSLOECK-GVHYBUMESA-N [(3r)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methanol Chemical compound C1CNCC2CN[C@@H](CO)CN21 SPZKTRAGSLOECK-GVHYBUMESA-N 0.000 description 4
239000000556 agonist Substances 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
229960001948 caffeine Drugs 0.000 description 4
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 4
FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
238000010828 elution Methods 0.000 description 4
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
208000024714 major depressive disease Diseases 0.000 description 4
229940127237 mood stabilizer Drugs 0.000 description 4
239000004050 mood stabilizer Substances 0.000 description 4
KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 4
VELLNKQOZGOHSI-GOTSBHOMSA-N n-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(6-fluoro-2-methylpyridin-3-yl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO)C=C(C=2C(=NC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VELLNKQOZGOHSI-GOTSBHOMSA-N 0.000 description 4
239000010502 orange oil Substances 0.000 description 4
231100000572 poisoning Toxicity 0.000 description 4
230000000607 poisoning effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 3
SZGFDFYGXXDQRW-UHFFFAOYSA-N (2-benzyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-8a-yl)methanol Chemical compound C1C2(CO)CCCN2CCN1CC1=CC=CC=C1 SZGFDFYGXXDQRW-UHFFFAOYSA-N 0.000 description 3
CTSBUHPWELFRGB-SECBINFHSA-N (2r)-2-(benzylamino)-3-hydroxypropanoic acid Chemical compound OC[C@H](C(O)=O)NCC1=CC=CC=C1 CTSBUHPWELFRGB-SECBINFHSA-N 0.000 description 3
GWEKLNLVVQWNSK-GVHYBUMESA-N (3r)-3-methyl-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazine Chemical compound C1CNCC2CN[C@H](C)CN21 GWEKLNLVVQWNSK-GVHYBUMESA-N 0.000 description 3
LAHROJZLGLNLBT-SNVBAGLBSA-N (3r)-4-benzyl-5-oxomorpholine-3-carboxylic acid Chemical compound OC(=O)[C@H]1COCC(=O)N1CC1=CC=CC=C1 LAHROJZLGLNLBT-SNVBAGLBSA-N 0.000 description 3
XZVHBJHXLYHSNN-LLVKDONJSA-N (3r)-4-benzylmorpholin-4-ium-3-carboxylate Chemical compound OC(=O)[C@H]1COCCN1CC1=CC=CC=C1 XZVHBJHXLYHSNN-LLVKDONJSA-N 0.000 description 3
FTTATHOUSOIFOQ-SSDOTTSWSA-N (8ar)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCC[C@@H]21 FTTATHOUSOIFOQ-SSDOTTSWSA-N 0.000 description 3
HAAZJWVQKLGNDT-ZCFIWIBFSA-N (8ar)-2,3,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-4-one Chemical compound O=C1CNC[C@H]2CCCN12 HAAZJWVQKLGNDT-ZCFIWIBFSA-N 0.000 description 3
SKVZOGYWWGUUFL-ZCFIWIBFSA-N (8ar)-2,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-3-one Chemical compound C1NC(=O)CN2CCC[C@@H]21 SKVZOGYWWGUUFL-ZCFIWIBFSA-N 0.000 description 3
JBIHMFNMKHDTEE-LURJTMIESA-N (8as)-3,4,6,7,8,8a-hexahydro-2h-pyrrolo[1,2-a]pyrazin-1-one Chemical compound O=C1NCCN2CCC[C@@H]12 JBIHMFNMKHDTEE-LURJTMIESA-N 0.000 description 3
WOROCRBYOJCNGP-MLWJPKLSSA-N (8s)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-8-ol Chemical compound C1CNCC2[C@@H](O)CCN21 WOROCRBYOJCNGP-MLWJPKLSSA-N 0.000 description 3
QXKAIPFKHPAPLY-ZETCQYMHSA-N (9as)-1,3,4,5,7,8,9,9a-octahydropyrrolo[1,2-d][1,4]diazepin-2-one Chemical compound C1CNC(=O)C[C@@H]2CCCN21 QXKAIPFKHPAPLY-ZETCQYMHSA-N 0.000 description 3
PXYNCQRQUOOTSQ-QMMMGPOBSA-N (9as)-2,3,4,5,7,8,9,9a-octahydro-1h-pyrrolo[1,2-d][1,4]diazepine Chemical compound C1CNCCN2CCC[C@H]21 PXYNCQRQUOOTSQ-QMMMGPOBSA-N 0.000 description 3
FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 3
IIZGWFQKLVCLLA-UHFFFAOYSA-N 1,4-bis[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(C(O)=O)C1 IIZGWFQKLVCLLA-UHFFFAOYSA-N 0.000 description 3
WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 3
RJQZEMYCWGPILN-UHFFFAOYSA-N 2,2-dioxo-3,4,6,7,8,9a-hexahydro-1h-pyrazino[2,1-c][1,4]thiazin-9-one Chemical compound C1CS(=O)(=O)CC2C(=O)NCCN21 RJQZEMYCWGPILN-UHFFFAOYSA-N 0.000 description 3
UUUPNGVYOIXAAC-UHFFFAOYSA-N 2,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-1-one Chemical compound C1CNCC2C(=O)NCCN21 UUUPNGVYOIXAAC-UHFFFAOYSA-N 0.000 description 3
VHNVKVILFAFJMN-UHFFFAOYSA-N 2,3,4,6,7,8-hexahydro-1h-pyrrolo[1,2-a]pyrazin-8a-ylmethanol Chemical compound C1CNCC2(CO)N1CCC2 VHNVKVILFAFJMN-UHFFFAOYSA-N 0.000 description 3
OYMJACTWCHNNBW-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-chloro-4-(4-methylpyridin-3-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(Cl)C=C(C=2C(=CC=NC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OYMJACTWCHNNBW-UHFFFAOYSA-N 0.000 description 3
ITSDZDVKNGECGP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-chloro-4-(6-fluoro-2-methylpyridin-3-yl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(Cl)C=C(C=2C(=NC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ITSDZDVKNGECGP-UHFFFAOYSA-N 0.000 description 3
BYYKMTONWNLJGJ-UHFFFAOYSA-N 3,3a,4,5,6,7-hexahydro-2h-[1,2]thiazolo[2,3-a]pyrazine 1,1-dioxide Chemical compound C1NCCN2S(=O)(=O)CCC21 BYYKMTONWNLJGJ-UHFFFAOYSA-N 0.000 description 3
DIYIRNCLLFDDON-UHFFFAOYSA-N 4-o-tert-butyl 3-o-methyl 1,1-dioxo-1,4-thiazinane-3,4-dicarboxylate Chemical compound COC(=O)C1CS(=O)(=O)CCN1C(=O)OC(C)(C)C DIYIRNCLLFDDON-UHFFFAOYSA-N 0.000 description 3
208000000044 Amnesia Diseases 0.000 description 3
208000031091 Amnestic disease Diseases 0.000 description 3
206010003805 Autism Diseases 0.000 description 3
208000020706 Autistic disease Diseases 0.000 description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
208000004230 Gender Dysphoria Diseases 0.000 description 3
208000004547 Hallucinations Diseases 0.000 description 3
229910010082 LiAlH Inorganic materials 0.000 description 3
OEQJXQTVCVCSKC-UHFFFAOYSA-N N1(CC=NC=C1)CO Chemical compound N1(CC=NC=C1)CO OEQJXQTVCVCSKC-UHFFFAOYSA-N 0.000 description 3
229940123257 Opioid receptor antagonist Drugs 0.000 description 3
208000006199 Parasomnias Diseases 0.000 description 3
206010034912 Phobia Diseases 0.000 description 3
201000001880 Sexual dysfunction Diseases 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
208000011963 Substance-induced psychotic disease Diseases 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
LIQVAYFMLUMDCQ-PZORYLMUSA-N [(3r)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1CNCC2CN[C@@H](CO[Si](C)(C)C(C)(C)C)CN21 LIQVAYFMLUMDCQ-PZORYLMUSA-N 0.000 description 3
LIQVAYFMLUMDCQ-STQMWFEESA-N [(3s,9as)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1CNC[C@H]2CN[C@H](CO[Si](C)(C)C(C)(C)C)CN21 LIQVAYFMLUMDCQ-STQMWFEESA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000006986 amnesia Effects 0.000 description 3
239000011260 aqueous acid Substances 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
150000001502 aryl halides Chemical class 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
150000007514 bases Chemical class 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
201000006145 cocaine dependence Diseases 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
SHKUOGVVYXRJKK-UHFFFAOYSA-N diethyl 1-(2-bromoacetyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CCCN1C(=O)CBr SHKUOGVVYXRJKK-UHFFFAOYSA-N 0.000 description 3
DHWOXCBGAJCELU-UHFFFAOYSA-N diethyl pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CCCN1 DHWOXCBGAJCELU-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012039 electrophile Substances 0.000 description 3
NFRFKIUDOXVXNV-GFCCVEGCSA-N ethyl (3r)-4-benzyl-5-oxomorpholine-3-carboxylate Chemical compound CCOC(=O)[C@H]1COCC(=O)N1CC1=CC=CC=C1 NFRFKIUDOXVXNV-GFCCVEGCSA-N 0.000 description 3
XVXRZXOBIJTJTR-CYBMUJFWSA-N ethyl (3r)-4-benzylmorpholine-3-carboxylate Chemical compound CCOC(=O)[C@H]1COCCN1CC1=CC=CC=C1 XVXRZXOBIJTJTR-CYBMUJFWSA-N 0.000 description 3
ZIXSCYRVDNLLQI-UHFFFAOYSA-N ethyl 2-benzyl-1,4-dioxo-3,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-8a-carboxylate Chemical compound O=C1C2(C(=O)OCC)CCCN2C(=O)CN1CC1=CC=CC=C1 ZIXSCYRVDNLLQI-UHFFFAOYSA-N 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
230000000147 hypnotic effect Effects 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
WTRIPTNBUAPENO-JTQLQIEISA-N methyl (2s)-1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1CCNC(=O)OC(C)(C)C WTRIPTNBUAPENO-JTQLQIEISA-N 0.000 description 3
APZJAKMMPQPRMG-FSPLSTOPSA-N methyl (2s,3s)-1-(2-chloroacetyl)-3-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1[C@@H](O)CCN1C(=O)CCl APZJAKMMPQPRMG-FSPLSTOPSA-N 0.000 description 3
FPZOEPPXPLBIAN-FHAQVOQBSA-N methyl (2s,3s)-3-hydroxypyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@H]1NCC[C@@H]1O FPZOEPPXPLBIAN-FHAQVOQBSA-N 0.000 description 3
ANJDRLZBIZGOSM-UHFFFAOYSA-N methyl 1,1-dioxo-1,4-thiazinane-3-carboxylate Chemical compound COC(=O)C1CS(=O)(=O)CCN1 ANJDRLZBIZGOSM-UHFFFAOYSA-N 0.000 description 3
KNUXIZKJOXRUOI-UHFFFAOYSA-N methyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,1-dioxo-1,4-thiazinane-3-carboxylate Chemical compound COC(=O)C1CS(=O)(=O)CCN1CCNC(=O)OC(C)(C)C KNUXIZKJOXRUOI-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
208000019906 panic disease Diseases 0.000 description 3
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
239000003444 phase transfer catalyst Substances 0.000 description 3
208000007100 phencyclidine abuse Diseases 0.000 description 3
208000019899 phobic disease Diseases 0.000 description 3
208000024335 physical disease Diseases 0.000 description 3
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
229960003770 reboxetine Drugs 0.000 description 3
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000011347 resin Substances 0.000 description 3
230000000698 schizophrenic effect Effects 0.000 description 3
239000003772 serotonin uptake inhibitor Substances 0.000 description 3
231100000872 sexual dysfunction Toxicity 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000000021 stimulant Substances 0.000 description 3
239000011593 sulfur Chemical group 0.000 description 3
239000003826 tablet Substances 0.000 description 3
SOGXYCNKQQJEED-MRVPVSSYSA-N tert-butyl (2r)-2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1CN SOGXYCNKQQJEED-MRVPVSSYSA-N 0.000 description 3
KVSZSDVGFRPYCD-SECBINFHSA-N tert-butyl (2r)-2-[[(2-chloroacetyl)amino]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1CNC(=O)CCl KVSZSDVGFRPYCD-SECBINFHSA-N 0.000 description 3
KVSZSDVGFRPYCD-VIFPVBQESA-N tert-butyl (2s)-2-[[(2-chloroacetyl)amino]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CNC(=O)CCl KVSZSDVGFRPYCD-VIFPVBQESA-N 0.000 description 3
PYCLKYVPYSJENJ-UHFFFAOYSA-N tert-butyl 1,1-dioxo-2,3,3a,4,6,7-hexahydro-[1,2]thiazolo[2,3-a]pyrazine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2S(=O)(=O)CCC21 PYCLKYVPYSJENJ-UHFFFAOYSA-N 0.000 description 3
DLGZEXCHQMTROA-UHFFFAOYSA-N tert-butyl 4-methylsulfonyl-3-(methylsulfonyloxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(S(C)(=O)=O)C(COS(C)(=O)=O)C1 DLGZEXCHQMTROA-UHFFFAOYSA-N 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
MGGVQZFQTOIVOD-PHDIDXHHSA-N (3r,9ar)-3-(hydroxymethyl)-3,6,7,8,9,9a-hexahydro-2h-pyrazino[1,2-a]pyrazine-1,4-dione Chemical compound C1NCCN2C(=O)[C@@H](CO)NC(=O)[C@H]21 MGGVQZFQTOIVOD-PHDIDXHHSA-N 0.000 description 2
JNTSDSBEAXSUAU-PHDIDXHHSA-N (7r,9ar)-7-(hydroxymethyl)-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]oxazine-6,9-dione Chemical compound C1OCCN2C(=O)[C@@H](CO)NC(=O)[C@H]21 JNTSDSBEAXSUAU-PHDIDXHHSA-N 0.000 description 2
YXMWPMAMMZJVEN-RITPCOANSA-N (7r,9ar)-7-(hydroxymethyl)-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]thiazine-6,9-dione Chemical compound C1SCCN2C(=O)[C@@H](CO)NC(=O)[C@@H]21 YXMWPMAMMZJVEN-RITPCOANSA-N 0.000 description 2
ZEKMVSOHQJAAHS-RITPCOANSA-N (7r,9ar)-7-(hydroxymethyl)-2,2-dioxo-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]thiazine-6,9-dione Chemical compound C1S(=O)(=O)CCN2C(=O)[C@@H](CO)NC(=O)[C@@H]21 ZEKMVSOHQJAAHS-RITPCOANSA-N 0.000 description 2
JNTSDSBEAXSUAU-ZBHICJROSA-N (7s)-7-(hydroxymethyl)-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]oxazine-6,9-dione Chemical compound C1OCCN2C(=O)[C@H](CO)NC(=O)C21 JNTSDSBEAXSUAU-ZBHICJROSA-N 0.000 description 2
YXMWPMAMMZJVEN-ZBHICJROSA-N (7s)-7-(hydroxymethyl)-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]thiazine-6,9-dione Chemical compound C1SCCN2C(=O)[C@H](CO)NC(=O)C21 YXMWPMAMMZJVEN-ZBHICJROSA-N 0.000 description 2
ZEKMVSOHQJAAHS-ZBHICJROSA-N (7s)-7-(hydroxymethyl)-2,2-dioxo-1,3,4,7,8,9a-hexahydropyrazino[2,1-c][1,4]thiazine-6,9-dione Chemical compound C1S(=O)(=O)CCN2C(=O)[C@H](CO)NC(=O)C21 ZEKMVSOHQJAAHS-ZBHICJROSA-N 0.000 description 2
VXDCVLLKNWIPLW-CABCVRRESA-N (7s,9as)-8-benzyl-7-(fluoromethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazine Chemical compound C([C@H]1COCCN1C[C@H]1CF)N1CC1=CC=CC=C1 VXDCVLLKNWIPLW-CABCVRRESA-N 0.000 description 2
FTTATHOUSOIFOQ-ZETCQYMHSA-N (8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCC[C@H]21 FTTATHOUSOIFOQ-ZETCQYMHSA-N 0.000 description 2
SKVZOGYWWGUUFL-LURJTMIESA-N (8as)-2,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-3-one Chemical compound C1NC(=O)CN2CCC[C@H]21 SKVZOGYWWGUUFL-LURJTMIESA-N 0.000 description 2
OPBSNAYKUYMJDO-UHFFFAOYSA-N 1,2,3,4,6,7-hexahydropyrrolo[1,2-a]pyrazine Chemical compound C1CNCC2=CCCN21 OPBSNAYKUYMJDO-UHFFFAOYSA-N 0.000 description 2
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
BSBHJJOSYCWCIO-LSDHHAIUSA-N 1-[(7s,9ar)-7-[[tert-butyl(dimethyl)silyl]oxymethyl]-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]ethanone Chemical compound C1[C@@H](CO[Si](C)(C)C(C)(C)C)NC[C@@H]2CN(C(=O)C)CCN21 BSBHJJOSYCWCIO-LSDHHAIUSA-N 0.000 description 2
AIUMSOSJFHKDDR-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]piperazine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCN1CCNC(=O)OC(C)(C)C AIUMSOSJFHKDDR-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 2
MUMSDEQXDJDQAA-UHFFFAOYSA-N 3,4,6,7,8,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-9-one Chemical compound C1COCC2C(=O)NCCN21 MUMSDEQXDJDQAA-UHFFFAOYSA-N 0.000 description 2
WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
BJBUEDPLEOHJGE-UHFFFAOYSA-N 3-hydroxyproline Chemical compound OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 2
LGWMTRPJZFEWCX-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC(C(O)=O)C1 LGWMTRPJZFEWCX-UHFFFAOYSA-N 0.000 description 2
KVXXEKIGMOEPSA-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOCC1C(O)=O KVXXEKIGMOEPSA-UHFFFAOYSA-N 0.000 description 2
WATXLILDVUDIBE-UHFFFAOYSA-N 4-o-tert-butyl 3-o-methyl thiomorpholine-3,4-dicarboxylate Chemical compound COC(=O)C1CSCCN1C(=O)OC(C)(C)C WATXLILDVUDIBE-UHFFFAOYSA-N 0.000 description 2
SNHPTAXKAIHTMH-UHFFFAOYSA-N 8-hydroxy-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1NCC(=O)N2C1C(O)CC2 SNHPTAXKAIHTMH-UHFFFAOYSA-N 0.000 description 2
208000008811 Agoraphobia Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010006550 Bulimia nervosa Diseases 0.000 description 2
HKHVSNFTFLZIHA-UHFFFAOYSA-N CC(C1C(NC2)=O)SCCN1C2=O Chemical compound CC(C1C(NC2)=O)SCCN1C2=O HKHVSNFTFLZIHA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
206010012239 Delusion Diseases 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
WLTCKEHCTUYJGI-UHFFFAOYSA-N Diethyl aminomalonate Chemical compound CCOC(=O)C(N)C(=O)OCC WLTCKEHCTUYJGI-UHFFFAOYSA-N 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
208000029810 Gender identity disease Diseases 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010021030 Hypomania Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
206010057672 Male sexual dysfunction Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
206010057852 Nicotine dependence Diseases 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
208000011962 Substance-induced mood disease Diseases 0.000 description 2
231100000395 Substance-induced mood disorder Toxicity 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
IYUKFAFDFHZKPI-AENDTGMFSA-N [(2r)-1-methoxy-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.COC(=O)[C@@H](C)N IYUKFAFDFHZKPI-AENDTGMFSA-N 0.000 description 2
YWUFLJZASFCVQJ-OLZOCXBDSA-N [(3r,8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1N[C@@H](CO[Si](C)(C)C(C)(C)C)CN2CCC[C@H]21 YWUFLJZASFCVQJ-OLZOCXBDSA-N 0.000 description 2
YWUFLJZASFCVQJ-STQMWFEESA-N [(3s,8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1N[C@H](CO[Si](C)(C)C(C)(C)C)CN2CCC[C@H]21 YWUFLJZASFCVQJ-STQMWFEESA-N 0.000 description 2
SPZKTRAGSLOECK-JGVFFNPUSA-N [(3s,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methanol Chemical compound C1CNC[C@@H]2CN[C@H](CO)CN21 SPZKTRAGSLOECK-JGVFFNPUSA-N 0.000 description 2
LIQVAYFMLUMDCQ-QWHCGFSZSA-N [(3s,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1CNC[C@@H]2CN[C@H](CO[Si](C)(C)C(C)(C)C)CN21 LIQVAYFMLUMDCQ-QWHCGFSZSA-N 0.000 description 2
SPZKTRAGSLOECK-YUMQZZPRSA-N [(3s,9as)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrazino[1,2-a]pyrazin-3-yl]methanol Chemical compound C1CNC[C@H]2CN[C@H](CO)CN21 SPZKTRAGSLOECK-YUMQZZPRSA-N 0.000 description 2
OPEBSOKNWMAPLB-GVHYBUMESA-N [(7r)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methanol Chemical compound C1COCC2CN[C@@H](CO)CN21 OPEBSOKNWMAPLB-GVHYBUMESA-N 0.000 description 2
OPEBSOKNWMAPLB-JGVFFNPUSA-N [(7s,9ar)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methanol Chemical compound C1COC[C@H]2CN[C@H](CO)CN21 OPEBSOKNWMAPLB-JGVFFNPUSA-N 0.000 description 2
208000029650 alcohol withdrawal Diseases 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
238000012435 analytical chromatography Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000037007 arousal Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
UHPHWVPAQZJMDO-GFCCVEGCSA-N benzyl n-[[(2r)-pyrrolidin-2-yl]methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC[C@H]1CCCN1 UHPHWVPAQZJMDO-GFCCVEGCSA-N 0.000 description 2
UHPHWVPAQZJMDO-LBPRGKRZSA-N benzyl n-[[(2s)-pyrrolidin-2-yl]methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC[C@@H]1CCCN1 UHPHWVPAQZJMDO-LBPRGKRZSA-N 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
229910000085 borane Inorganic materials 0.000 description 2
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229960001058 bupropion Drugs 0.000 description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
201000001843 cannabis dependence Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
235000019788 craving Nutrition 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
231100000868 delusion Toxicity 0.000 description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
XAUBVKTVEYQFBI-MRXNPFEDSA-N diethyl 2-[(2r)-2-(phenylmethoxycarbonylaminomethyl)pyrrolidin-1-yl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)N1CCC[C@@H]1CNC(=O)OCC1=CC=CC=C1 XAUBVKTVEYQFBI-MRXNPFEDSA-N 0.000 description 2
XAUBVKTVEYQFBI-INIZCTEOSA-N diethyl 2-[(2s)-2-(phenylmethoxycarbonylaminomethyl)pyrrolidin-1-yl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)N1CCC[C@H]1CNC(=O)OCC1=CC=CC=C1 XAUBVKTVEYQFBI-INIZCTEOSA-N 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
229960003530 donepezil Drugs 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
BZWBLIFZCYXCGB-GVHYBUMESA-N ethyl (8ar)-3-oxo-2,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-4-carboxylate Chemical compound C1NC(=O)C(C(=O)OCC)N2CCC[C@@H]21 BZWBLIFZCYXCGB-GVHYBUMESA-N 0.000 description 2
BZWBLIFZCYXCGB-JAMMHHFISA-N ethyl (8as)-3-oxo-2,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-4-carboxylate Chemical compound C1NC(=O)C(C(=O)OCC)N2CCC[C@H]21 BZWBLIFZCYXCGB-JAMMHHFISA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
238000000105 evaporative light scattering detection Methods 0.000 description 2
206010016531 fetishism Diseases 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000012025 fluorinating agent Substances 0.000 description 2
125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
229960003980 galantamine Drugs 0.000 description 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
206010020765 hypersomnia Diseases 0.000 description 2
239000005457 ice water Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
150000003951 lactams Chemical group 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
238000011068 loading method Methods 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
NDBQJIBNNUJNHA-DFWYDOINSA-N methyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CO NDBQJIBNNUJNHA-DFWYDOINSA-N 0.000 description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
229960001344 methylphenidate Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
VSEKEMQDOIJVFY-UHFFFAOYSA-N n',n'-dimethylmethanediamine Chemical compound CN(C)CN VSEKEMQDOIJVFY-UHFFFAOYSA-N 0.000 description 2
HSTIXJRMMOLLKM-ZEQRLZLVSA-N n-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-methylpyridin-3-yl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO)C=C(C=2C(=CC=NC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HSTIXJRMMOLLKM-ZEQRLZLVSA-N 0.000 description 2
LDTMTPUCOIHWIK-UKOKCHKQSA-N n-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-methylpyridin-3-yl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide;hydrochloride Chemical compound Cl.C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO)C=C(C=2C(=CC=NC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LDTMTPUCOIHWIK-UKOKCHKQSA-N 0.000 description 2
PSLBTECNMOCNOZ-VMPREFPWSA-N n-[6-[(7s,9as)-7-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-methylpyridin-3-yl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO[Si](C)(C)C(C)(C)C)C=C(C=2C(=CC=NC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PSLBTECNMOCNOZ-VMPREFPWSA-N 0.000 description 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
229960003086 naltrexone Drugs 0.000 description 2
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
208000024309 orgasm disease Diseases 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
125000005880 oxathiolanyl group Chemical group 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229960000761 pemoline Drugs 0.000 description 2
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000008447 perception Effects 0.000 description 2
230000002688 persistence Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000005191 phase separation Methods 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002600 positron emission tomography Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000004237 preparative chromatography Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
LFCWHDGQCWJKCG-UHFFFAOYSA-N pyrazin-2-ylmethanol Chemical compound OCC1=CN=CC=N1 LFCWHDGQCWJKCG-UHFFFAOYSA-N 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
229960001153 serine Drugs 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
238000002603 single-photon emission computed tomography Methods 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
239000011343 solid material Substances 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000013077 target material Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
MCFFCQNSBLVXKS-OAHLLOKOSA-N tert-butyl (2r)-2-(phenylmethoxycarbonylaminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1CNC(=O)OCC1=CC=CC=C1 MCFFCQNSBLVXKS-OAHLLOKOSA-N 0.000 description 2
SOGXYCNKQQJEED-QMMMGPOBSA-N tert-butyl (2s)-2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CN SOGXYCNKQQJEED-QMMMGPOBSA-N 0.000 description 2
MCFFCQNSBLVXKS-HNNXBMFYSA-N tert-butyl (2s)-2-(phenylmethoxycarbonylaminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CNC(=O)OCC1=CC=CC=C1 MCFFCQNSBLVXKS-HNNXBMFYSA-N 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XICAMVNHDMHQHG-UHFFFAOYSA-N thiomorpholine-4-carboxylic acid Chemical compound OC(=O)N1CCSCC1 XICAMVNHDMHQHG-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
229910052723 transition metal Inorganic materials 0.000 description 2
150000003624 transition metals Chemical class 0.000 description 2
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
229960000604 valproic acid Drugs 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 description 1
XOFNMNLYGPKKOV-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1Cl XOFNMNLYGPKKOV-UHFFFAOYSA-N 0.000 description 1
DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
NIODDMURQJWDSI-RGMNGODLSA-N (2S)-2-pyrrolidin-1-ylpropanoic acid hydrochloride Chemical compound Cl.OC(=O)[C@H](C)N1CCCC1 NIODDMURQJWDSI-RGMNGODLSA-N 0.000 description 1
KVXXEKIGMOEPSA-SSDOTTSWSA-N (3r)-4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC[C@@H]1C(O)=O KVXXEKIGMOEPSA-SSDOTTSWSA-N 0.000 description 1
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
QKOJLMKWBRBZNQ-UHFFFAOYSA-N (5-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=CC=C(F)C=C1B(O)O QKOJLMKWBRBZNQ-UHFFFAOYSA-N 0.000 description 1
GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
UJIDITIXXKVIMJ-CHWSQXEVSA-N (7r,9ar)-8-benzyl-7-(hydroxymethyl)-3,4,7,9a-tetrahydro-1h-pyrazino[2,1-c][1,4]oxazine-6,9-dione Chemical compound N1([C@@H](C(N2CCOC[C@@H]2C1=O)=O)CO)CC1=CC=CC=C1 UJIDITIXXKVIMJ-CHWSQXEVSA-N 0.000 description 1
WMLFSOAMHHUBQL-SFYZADRCSA-N (7s,9as)-7-(fluoromethyl)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine Chemical compound C1COC[C@@H]2CN[C@H](CF)CN21 WMLFSOAMHHUBQL-SFYZADRCSA-N 0.000 description 1
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
BHFXPKPIPBNKFI-ZCFIWIBFSA-N (8ar)-2,3,4,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-6-one Chemical compound C1NCCN2C(=O)CC[C@@H]21 BHFXPKPIPBNKFI-ZCFIWIBFSA-N 0.000 description 1
HAAZJWVQKLGNDT-LURJTMIESA-N (8as)-2,3,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-4-one Chemical compound O=C1CNC[C@@H]2CCCN12 HAAZJWVQKLGNDT-LURJTMIESA-N 0.000 description 1
XODXWMXYGYWAQL-ZETCQYMHSA-N (9as)-2,3,4,5,7,8,9,9a-octahydropyrrolo[1,2-a][1,4]diazepin-1-one Chemical compound O=C1NCCCN2CCC[C@@H]12 XODXWMXYGYWAQL-ZETCQYMHSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
WOVXYKRDBDKEOK-UHFFFAOYSA-N 1,3,4,6,7,8-hexahydropyrazino[2,1-c][1,4]oxazine Chemical compound C1OCCN2C1=CNCC2 WOVXYKRDBDKEOK-UHFFFAOYSA-N 0.000 description 1
ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
MAMGQKYBCOXNOO-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C1(C(=O)O)CC1 MAMGQKYBCOXNOO-UHFFFAOYSA-N 0.000 description 1
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
IQKOVLZJPVVLOZ-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl piperazine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCN1 IQKOVLZJPVVLOZ-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
BHFXPKPIPBNKFI-UHFFFAOYSA-N 2,3,4,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-6-one Chemical compound C1NCCN2C(=O)CCC21 BHFXPKPIPBNKFI-UHFFFAOYSA-N 0.000 description 1
NPLSMQWSKZXZPD-UHFFFAOYSA-N 2,3-dihydropyrrol-1-amine Chemical compound NN1CCC=C1 NPLSMQWSKZXZPD-UHFFFAOYSA-N 0.000 description 1
YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
GPIQHPBJRAPFDV-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(Cl)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GPIQHPBJRAPFDV-UHFFFAOYSA-N 0.000 description 1
SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 description 1
NECMIXDTENBWRG-UHFFFAOYSA-N 2h-pyrazine-1-carboxylic acid Chemical compound OC(=O)N1CC=NC=C1 NECMIXDTENBWRG-UHFFFAOYSA-N 0.000 description 1
DPVSPOJGBBOZGB-UHFFFAOYSA-N 3,6,7,8,9,9a-hexahydro-2h-pyrazino[1,2-a]pyrazine-1,4-dione Chemical compound C1CNCC2C(=O)NCC(=O)N21 DPVSPOJGBBOZGB-UHFFFAOYSA-N 0.000 description 1
HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
UBHMOCPFHJWSDZ-UHFFFAOYSA-N 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine Chemical compound CC1=CC(F)=CC=C1C1=CC(Cl)=NC=C1N UBHMOCPFHJWSDZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
208000017194 Affective disease Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
208000036640 Asperger disease Diseases 0.000 description 1
201000006062 Asperger syndrome Diseases 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
QORQZMBCPRBCAB-UHFFFAOYSA-M Butabarbital sodium Chemical compound [Na+].CCC(C)C1(CC)C(=O)NC([O-])=NC1=O QORQZMBCPRBCAB-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
201000006306 Cor pulmonale Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
229930195711 D-Serine Natural products 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
206010012225 Delirium tremens Diseases 0.000 description 1
208000024254 Delusional disease Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
239000004278 EU approved seasoning Substances 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
206010057671 Female sexual dysfunction Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
208000001271 Inhalant Abuse Diseases 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010026864 Masochism Diseases 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
206010027944 Mood disorder due to a general medical condition Diseases 0.000 description 1
AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
QUYZZTTYATWSRY-UHFFFAOYSA-N N1C=CC=C2N=CC=C12 Chemical compound N1C=CC=C2N=CC=C12 QUYZZTTYATWSRY-UHFFFAOYSA-N 0.000 description 1
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
102100029409 Neuromedin-K receptor Human genes 0.000 description 1
206010029412 Nightmare Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
229940123176 Opioid kappa receptor antagonist Drugs 0.000 description 1
229940118548 Opioid mu receptor agonist Drugs 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033664 Panic attack Diseases 0.000 description 1
206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
208000032769 Pedophilia Diseases 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
208000006289 Rett Syndrome Diseases 0.000 description 1
208000036353 Rett disease Diseases 0.000 description 1
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
206010039367 Sadism Diseases 0.000 description 1
ZRIHAIZYIMGOAB-UHFFFAOYSA-N Secbutobarbitone Natural products CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
208000000810 Separation Anxiety Diseases 0.000 description 1
208000019568 Shared Paranoid disease Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
206010041347 Somnambulism Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
229940124237 Testosterone receptor antagonist Drugs 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
WSHDBTQQKKWIIQ-SFYZADRCSA-N [(3r,8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-3-yl]methanol Chemical compound C1N[C@@H](CO)CN2CCC[C@H]21 WSHDBTQQKKWIIQ-SFYZADRCSA-N 0.000 description 1
NRXLIJQSCALMCI-RKDXNWHRSA-N [(3r,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-pyrido[1,2-a]pyrazin-3-yl]methanol Chemical compound C1CCC[C@@H]2CN[C@@H](CO)CN21 NRXLIJQSCALMCI-RKDXNWHRSA-N 0.000 description 1
IRLPJUXYSAAKGO-CHWSQXEVSA-N [(7r,9ar)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazin-7-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C1COC[C@H]2CN[C@@H](CO[Si](C)(C)C(C)(C)C)CN21 IRLPJUXYSAAKGO-CHWSQXEVSA-N 0.000 description 1
BGOIXGISFIPPPW-PMACEKPBSA-N [(7s,9as)-8-benzyl-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-7-yl]methoxy-tert-butyl-dimethylsilane Chemical compound C([C@H]1COCCN1C[C@H]1CO[Si](C)(C)C(C)(C)C)N1CC1=CC=CC=C1 BGOIXGISFIPPPW-PMACEKPBSA-N 0.000 description 1
PWLPKNYWXJOFKL-GVHYBUMESA-N [(8ar)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-4-yl]methanol Chemical compound OCC1CNC[C@H]2CCCN12 PWLPKNYWXJOFKL-GVHYBUMESA-N 0.000 description 1
WSHDBTQQKKWIIQ-MQWKRIRWSA-N [(8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-3-yl]methanol Chemical compound C1NC(CO)CN2CCC[C@H]21 WSHDBTQQKKWIIQ-MQWKRIRWSA-N 0.000 description 1
PWLPKNYWXJOFKL-JAMMHHFISA-N [(8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-4-yl]methanol Chemical compound OCC1CNC[C@@H]2CCCN12 PWLPKNYWXJOFKL-JAMMHHFISA-N 0.000 description 1
YADPKIAGCVAODE-UHFFFAOYSA-N [1-butoxy-3-[3-(2-carbamoyloxy-2-pentoxyethyl)-5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl]propan-2-yl] carbamate;[1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl] carbamate;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O.O=C1N(CC(COCCCC)OC(N)=O)C(=O)NC(=O)C1(CC)C1=CC=CC=C1.O=C1N(CC(OCCCCC)OC(N)=O)C(=O)N(CC(COCCCC)OC(N)=O)C(=O)C1(CC)C1=CC=CC=C1 YADPKIAGCVAODE-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
229960004047 acamprosate Drugs 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000026345 acute stress disease Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
229960000711 alprostadil Drugs 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
238000010976 amide bond formation reaction Methods 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
BNUHTPRRZIDNHE-UHFFFAOYSA-N aminomethyl pyrrolidine-1-carboxylate Chemical compound NCOC(=O)N1CCCC1 BNUHTPRRZIDNHE-UHFFFAOYSA-N 0.000 description 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
201000002472 amphetamine abuse Diseases 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940070021 anabolic steroids Drugs 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
208000024823 antisocial personality disease Diseases 0.000 description 1
239000002948 appetite stimulant Substances 0.000 description 1
229940029995 appetite stimulants Drugs 0.000 description 1
UORJNBVJVRLXMQ-UHFFFAOYSA-N aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
229960003153 aprobarbital Drugs 0.000 description 1
229960004372 aripiprazole Drugs 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229960002430 atomoxetine Drugs 0.000 description 1
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
208000029560 autism spectrum disease Diseases 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
229960001081 benzatropine Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960003003 biperiden Drugs 0.000 description 1
YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
208000030963 borderline personality disease Diseases 0.000 description 1
125000005620 boronic acid group Chemical class 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
229940015694 butabarbital Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
201000009322 cannabis abuse Diseases 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
208000024825 childhood disintegrative disease Diseases 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
229960004414 clomethiazole Drugs 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
201000001272 cocaine abuse Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
208000030964 dependent personality disease Diseases 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
125000005959 diazepanyl group Chemical group 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
229960004341 escitalopram Drugs 0.000 description 1
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
229960002336 estazolam Drugs 0.000 description 1
CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000011194 food seasoning agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
229960002870 gabapentin Drugs 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
229960005219 gentisic acid Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000002270 hallucinogen abuse Diseases 0.000 description 1
201000006138 hallucinogen dependence Diseases 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000014674 injury Diseases 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
229960001848 lamotrigine Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
AXPPAKIFWZPHCR-UHFFFAOYSA-N lithium;bis[ethyl(dimethyl)silyl]azanide Chemical compound [Li+].CC[Si](C)(C)[N-][Si](C)(C)CC AXPPAKIFWZPHCR-UHFFFAOYSA-N 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
229960005209 lofexidine Drugs 0.000 description 1
KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
229960004033 lormetazepam Drugs 0.000 description 1
229960000423 loxapine Drugs 0.000 description 1
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000015421 male orgasm disease Diseases 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229960004090 maprotiline Drugs 0.000 description 1
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
229960000300 mesoridazine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002032 methanolic fraction Substances 0.000 description 1
BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
229960003955 mianserin Drugs 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
229960001785 mirtazapine Drugs 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
229960004644 moclobemide Drugs 0.000 description 1
229960001165 modafinil Drugs 0.000 description 1
229960004938 molindone Drugs 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
229960001800 nefazodone Drugs 0.000 description 1
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000002670 nicotine replacement therapy Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
230000001777 nootropic effect Effects 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
201000000988 opioid abuse Diseases 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000010653 organometallic reaction Methods 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
208000014451 palmoplantar keratoderma and congenital alopecia 2 Diseases 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
208000002851 paranoid schizophrenia Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
239000006187 pill Substances 0.000 description 1
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960005253 procyclidine Drugs 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000004172 quinoline yellow Substances 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
229960004136 rivastigmine Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000007789 sealing Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
229960002060 secobarbital Drugs 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000004799 sedative–hypnotic effect Effects 0.000 description 1
208000025874 separation anxiety disease Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
201000005814 sexual masochism Diseases 0.000 description 1
208000027599 sexual masochism disease Diseases 0.000 description 1
201000005841 sexual sadism Diseases 0.000 description 1
208000027596 sexual sadism disease Diseases 0.000 description 1
229960003310 sildenafil Drugs 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
201000006152 substance dependence Diseases 0.000 description 1
201000006137 substance-induced psychosis Diseases 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
230000006103 sulfonylation Effects 0.000 description 1
238000005694 sulfonylation reaction Methods 0.000 description 1
RMCMCFUBWGCJLE-UHFFFAOYSA-N sulfuric acid;4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound OS(O)(=O)=O.C1CC2(C)C(=O)CC1C2(C)C RMCMCFUBWGCJLE-UHFFFAOYSA-N 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
YCBIIKJJHNZXFC-SNVBAGLBSA-N tert-butyl (2r)-2-[[(2-methoxy-2-oxoethyl)amino]methyl]pyrrolidine-1-carboxylate Chemical compound COC(=O)CNC[C@H]1CCCN1C(=O)OC(C)(C)C YCBIIKJJHNZXFC-SNVBAGLBSA-N 0.000 description 1
YDBPZCVWPFMBDH-MRVPVSSYSA-N tert-butyl (2r)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C=O YDBPZCVWPFMBDH-MRVPVSSYSA-N 0.000 description 1
FLJOPEJWNWDBDV-IAGOWNOFSA-N tert-butyl (3r)-3-[benzyl-[(2r)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]carbamoyl]morpholine-4-carboxylate Chemical compound O=C([C@@H]1N(CCOC1)C(=O)OC(C)(C)C)N([C@H](CO)C(=O)OC)CC1=CC=CC=C1 FLJOPEJWNWDBDV-IAGOWNOFSA-N 0.000 description 1
ZZKXXDPRBHMOAA-UHFFFAOYSA-N tert-butyl 2-amino-3-oxopropanoate Chemical compound CC(C)(C)OC(=O)C(N)C=O ZZKXXDPRBHMOAA-UHFFFAOYSA-N 0.000 description 1
NSILYQWHARROMG-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(CO)C1 NSILYQWHARROMG-UHFFFAOYSA-N 0.000 description 1
FLFCIHGLRXTHAA-RGURZIINSA-N tert-butyl 3-[[(2s)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]carbamoyl]thiomorpholine-4-carboxylate Chemical compound COC(=O)[C@H](CO)NC(=O)C1CSCCN1C(=O)OC(C)(C)C FLFCIHGLRXTHAA-RGURZIINSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
229960001918 tiagabine Drugs 0.000 description 1
208000016686 tic disease Diseases 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
229960004394 topiramate Drugs 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
229960001032 trihexyphenidyl Drugs 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
206010046947 vaginismus Diseases 0.000 description 1
229960002381 vardenafil Drugs 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
229960004010 zaleplon Drugs 0.000 description 1
HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
229960000607 ziprasidone Drugs 0.000 description 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
229960001475 zolpidem Drugs 0.000 description 1
ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
229960000820 zopiclone Drugs 0.000 description 1

JP2008529564A 2005-09-09 2006-09-07 ピリジン誘導体および精神異常の処置におけるそれらの使用 Active JP5121716B2 (ja)